Antares Pharma, Inc. (NASDAQ: ATRS) today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) ...
Certain adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis (pJIA), after treatment with other medicines including non-steroidal ...
Shares of self injection drug delivery technology company Antares Pharma, Inc. (ATRS) are trading higher on Monday after the U.S. Food and Drug Administration approved Otrexup, a once-per-week ...
• Antares Pharma Inc., of Ewing, N.J., reported FDA approval of Otrexup (methotrexate) injection, a version of methotrexate for once weekly self-administration with a single dose, disposable auto ...
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has received a Notice of Issuance from the U. S. Patent Office for patent number 8,480,631 entitled “Hazardous ...
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for OTREXUP™, a ...
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.S. Patent 8,579,865. This new patent is related to a previously issued U.S. patent 8,480,631, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback